Leigh disease Pipeline Summary

DelveInsight’s, “Leigh disease - Pipeline Insight, 2026” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Leigh disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Leigh disease: Understanding

Leigh disease: Overview

Leigh syndrome (LS) is a rare, incurable mitochondrial disorder that typically manifests during infancy or early childhood. In 1951, Prof. Denis Leigh defined subacute necrotizing encephalomyelopathy as a neuropathological disorder characterized by the early development of symmetric, necrotizing lesions in the grey matter of the brainstem, subthalamic region, and basal ganglia, often extending to deep cerebellar structures and the rostral spinal cord. These lesions are associated with neuronal loss, an initial inflammatory response followed by gliosis, and persistent capillary proliferation. These characteristic neuropathological features are considered essential for the diagnosis of Leigh syndrome and, although less clearly defined, Leigh-like syndromes.

Leigh syndrome presents with a broad spectrum of neurological manifestations, including movement disorders, axial hypotonia, spastic tetraparesis, respiratory abnormalities, ocular movement disturbances, ataxia, hearing impairment, and occasionally optic atrophy. Psychomotor regression, cognitive delay, or developmental stagnation may also occur. Symptoms often emerge following an infection after a variable symptom-free period of up to 6 months, which can precipitate rapid neurological deterioration. Dysmorphic features and major congenital malformations are generally absent, while cardiac involvement, prominent myopathy, and ragged-red fibers are uncommon; peripheral neuropathy and occasional proximal renal tubular dysfunction may occur. Serum lactate levels are typically elevated, with metabolic acidosis sometimes developing during infections. Leigh syndrome is usually a rapidly progressive disorder, with most affected individuals rarely surviving beyond the first decade, although late-onset and adult cases have been documented. Biochemically, the disease results from impaired mitochondrial bioenergetics caused by pathogenic variants in either nuclear or mitochondrial DNA. Complex I defects are frequently implicated, while SURF1 loss-of-function variants, affecting cytochrome c oxidase assembly, represent the most common nuclear DNA cause of Leigh syndrome.

The diagnosis of Leigh syndrome involves a combination of biochemical, electrophysiological, neuroimaging, muscle, and genetic assessments. Laboratory findings may include elevated blood and CSF lactate and/or pyruvate, an increased lactate/pyruvate ratio, elevated creatine kinase when muscle involvement is present, and characteristic urinary abnormalities such as increased methylmalonic acid, Krebs cycle intermediates, or 3-methylglutaconic/3-methylglutaric acids, depending on the underlying variant; reduced coenzyme Q levels may also occur in selected cases. Electrophysiological investigations can identify abnormal spontaneous activity on electromyography, peripheral neuropathy on nerve-conduction studies, prolonged auditory brainstem responses, abnormalities in visual evoked potentials, and epileptiform changes or hypsarrhythmia on EEG. Brain MRI typically demonstrates bilateral, symmetrical T2 hyperintensities involving the basal ganglia and brainstem, with possible white-matter abnormalities, ventricular enlargement, microcephaly, or intracranial pseudocysts; however, lesions may evolve, regress, or be absent early in the disease, and therefore a normal MRI does not exclude Leigh syndrome. Proton magnetic resonance spectroscopy may further support the diagnosis by demonstrating a lactate peak. Muscle biopsy can be used to evaluate oxidative phosphorylation (OXPHOS) defects when clinically indicated, while cultured skin fibroblasts may provide complementary information when muscle tissue is unavailable or biopsy findings require clarification. Genetic testing is central to diagnosis and may include full mtDNA sequencing, analysis of POLG in suspected mtDNA depletion, targeted nuclear-gene testing, or broader next-generation sequencing approaches such as multigene panels or exome sequencing. Finally, genetic counseling is recommended to clarify the molecular cause, inheritance pattern, recurrence risk, and implications for future family planning.

No definitive treatment for Leigh syndrome (LS) is currently available, and management primarily includes supportive therapies such as coenzyme Q10 and its derivatives, vitamins, pyruvate, dichloroacetate, carnitine, and ketogenic or other targeted dietary interventions. Targeted vitamin therapy, particularly thiamine and biotin for SLC19A3-related disease, may provide rapid clinical benefit, whereas the efficacy of carnitine and N-acetylcysteine remains uncertain. Ketogenic or substrate-restricted diets may benefit selected genetic subtypes but can also cause metabolic complications. Several promising approaches remain experimental, including spindle nuclear transfer to prevent transmission of pathogenic mtDNA, AAV-based gene replacement, mitochondrial transfer, SIRT1 activation through NAD+ precursors or PARP inhibition, and mTOR inhibition with rapamycin.

"Leigh disease- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Leigh disease pipeline landscape is provided which includes the disease overview and Leigh disease treatment guidelines. The assessment part of the report embraces, in depth Leigh disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Leigh disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Leigh disease R&D. The therapies under development are focused on novel approaches to treat/improve Leigh disease.

Leigh disease Emerging Drugs Chapters

This segment of the Leigh disease report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Leigh disease Emerging Drugs

TTI-0102: Thiogenesis Therapeutics

TTI-0102 is an investigational cysteamine prodrug being developed by Thiogenesis for Leigh Syndrome Spectrum (LSS), a progressive mitochondrial disorder with no approved therapies. Its proposed mechanism is to support glutathione production and antioxidant defense, while increasing taurine and coenzyme A, potentially improving mitochondrial redox balance and cellular function. Thiogenesis has an FDA-cleared IND for a Phase IIa LSS trial planned for 2026, and the FDA granted TTI-0102 Rare Pediatric Disease designation in July 2026. Early biomarker findings from its Phase II MELAS study have informed the Leigh Syndrome development program, but clinical efficacy in Leigh Syndrome remains unproven.

Further product details are provided in the report……..

Leigh disease: Therapeutic Assessment

This segment of the report provides insights about the different Leigh disease drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Leigh disease
• There are approx. 3+ key companies which are developing the therapies for Leigh disease. The companies which have their Leigh disease drug candidates in the most advanced stage, i.e. Phase II include, Thiogenesis Therapeutics.

• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Leigh disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Leigh disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Leigh disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Leigh disease drugs.

Leigh disease Report Insights

• Leigh disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Leigh disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Leigh disease drugs?
• How many Leigh disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Leigh disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Leigh disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Leigh disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Thiogenesis Therapeutics
• Neurocores

Key Products

• TTI-0102
• KIT-20